South Korea Invossa Incident Raises Suspicions About Regulators, Sponsor At Local Forum
Controversy over Kolon Life Science’s gene therapy Invossa continue to escalate with participants in a recent forum led by the country’s progressive political party raising suspicions over the company and drug authorities; they called for a re-examination of the current drug approval and development process and halt on further easing of regulations.
You may also be interested in...
After selecting the bio-health sector as one of three major industries to nurture, South Korea unveils new strategy to triple the industry’s global market share and improve regulations in line with global standards, with a focus on the pharma and medical device sectors. While industry supports the move, some uncertainties could slow the government’s efforts.
While the eventual fate of Kolon Life’s gene therapy Invossa is still undecided after interim results from an ongoing probe into its composition, controversy over the product is growing as patients seek compensation from the company and government, and calls grow for a wider investigation.
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.